If they can get their pill approved for AD then any basic calculation puts the valuation way above £100, we'd probably be talking more over $1,000 a share though people tend to be embarrissed to say those kind of numbers. These were the valuations Mayo gave just for FDA approval just for AD just in USA and the assumptions in the calc didn't seem that extreme - https://www.sotcanalytics.com/archive-2023 (scroll a third of the way down). Therefore when you say "if the price is right it's bye bye". It's hard to see how any BO price could tempt the management as things stand. Sounds more like you're trying to reassure yourself because you have a fear lurking in the back of your mind of a massive sp increase at some point. You should be happy for us if we get the huge sp increase some of us can join you in giving $7 million odd to charity each year.
Market Data 
Markets 
